The headlines sound too good to be true: Lose 20% of your body weight! Reverse diabetes! The game-changer in metabolic health! You feel a flicker of hope and then the questions begin: Is this my answer
July 2024: A study linking patients with type 2 diabetes who were taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to an increased risk of a rare and serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION)
8.4 Clinical differentiation in a post-GLP-1 landscape The success of incretin-based therapies has raised expectations for efficacy in metabolic disease, particularly in obesity, where benchmarks for weight loss and cardiometabolic improvement are now well established (Kushner and Kahan, 2024)
Peripheral mechanisms 12 regulate appetite by monitoring the stomach's actions, such as how quickly it empties, which helps signal to the brain when we're full
Velocity Clinical Research is currently recruiting participants for a phase 3 clinical trial of retatrutide
The question, as always with resM, is whether the specific strain (RSB11) at the specific dose in the specific product produces clinically meaningful effects in humans
